1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Scandinavian ChemoTech AB (publ)

Scandinavian ChemoTech AB (publ)

CMOTEC-B.ST
Scandinavian ChemoTech AB (publ)SE flagStockholm Stock Exchange
3.79
SEK
-0.01
- -
90.21MMarket Cap
Scandinavian ChemoTech AB (publ)
CMOTEC-B.ST
(Stockholm Stock Exchange)

Recent

price

3.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.01
- -
0.35
0.16
0.02
0.01
0.04
0.15
0.28
0.48
0.52
Revenue per Share
-0.02
-0.99
- -
-2.4
-3.62
-1.85
-1.84
-1.89
-1.13
-0.59
-0.32
-0.26
Basic EPS, GAAP
-0.05
0.48
- -
-2.57
-4.56
-1.64
-2.32
-1.65
-1.02
-0.57
-0.16
-0.15
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.04
-0.93
- -
-7.15
-3.12
-1.37
-1.34
-1.39
-0.65
-0.09
0.18
- -
Book Value per Share
0.02
-1.82
- -
1.97
-0.63
-0.41
1.22
0.38
0.19
0.02
-0.02
-0.07
Tangible Book Value per Share
1
1
1
3
3
6
10
12
19
23
25
24
Basic Weighted Avg Shares
- -
- -
- -
1
1
- -
- -
- -
3
7
12
13
Sales/Revenue/Turnover
- -
-8,270.12
- -
-699.15
-2,153.06
-8,266.41
-34,851.02
-4,421.14
-717.12
-194.88
-52.61
-41.83
Operating Margin (%)
- -
- -
- -
1
2
2
3
3
3
2
2
2
Depreciation Expense
- -
-1
- -
-8
-12
-12
-18
-23
-21
-14
-8
-6
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-8,498.88
- -
-693.88
-2,216.73
-8,903.82
-36,210.2
-4,808.88
-747.38
-208.91
-65.58
-50.01
Profit Margin (%)
- -
-1
- -
7
-2
-3
12
4
3
- -
-1
-2
Working Capital
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
- -
16
10
9
24
14
11
6
3
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
25
Market Capitalization
166
120
90

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13
9
7
Cash, Cash Equivalents & STI
4
4
1
Accounts Receivable, Net
5
1
3
Inventories
4
3
3
Total Current Liabilities
11
10
9
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
0.76%
-46.72%
Free Cash Flow
- -
0.43%
-68.3%
Net Income, GAAP
- -
-0.64%
-41.27%
Sales/Revenue/Turnover
- -
303.82%
87.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
2
1
2
7
2025
2
4
3
3
12
2026
3
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.17
-0.23
-0.14
-0.14
-0.59
2025
-0.14
-0.04
-0.05
-0.1
-0.32
2026
-0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
E-therapeutics Plc (ETXPF)
Jupiter Neurosciences, Inc. (JUNS)
Alkermes plc Ordinary Shares Ex-distribution When Issued (ALKSV)
Century Therapeutics, Inc. (IPSC)
BetterLife Pharma Inc. (BETR.CN)
MiMedx Group, Inc. (MDXG)
Business
Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST) develops and commercializes DiffuSureTM, a minimally invasive electrochemical treatment method for solid tumors that employs diffusional spreading of cytotoxic substances directly into cancerous tissue to minimize damage to surrounding healthy areas; the company offers related medical devices, clinical support services, and ongoing research programs focused on oncology applications such as liver, pancreatic, and breast cancer treatments. Founded in 2013 and headquartered in Lund, Sweden, ChemoTech operates primarily in the European medtech sector, targeting hospitals, clinics, and healthcare providers across Scandinavia and select international markets including partnerships in the United States and Asia. The company's product pipeline includes the CE-marked DiffuSureTM applicator system and associated chemotherapy agents, with services encompassing training, regulatory compliance assistance, and clinical trial collaborations. In the past 1-2 years, ChemoTech has pursued strategic expansions including a key partnership with a leading U.S. medical device distributor in 2024 to accelerate market entry into North America; completed a SEK 50 million rights issue funding round in early 2025 to support Phase II clinical trials; and launched an upgraded DiffuSureTM 2.0 version featuring enhanced precision electrodes for deeper tumor penetration. These initiatives follow a 2023 reorganization that streamlined operations for faster regulatory approvals in the EU and FDA pathways, alongside the acquisition of a complementary biopsy tool subsidiary to broaden its minimally invasive oncology portfolio. ChemoTech continues to focus on global scaling, with recent alliances in Asia for pilot programs in high-prevalence cancer regions.